Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.62 |
| ▸ | BCHE | P06276 | 3/20 | 0.59 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.59 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CDK4 | P11802 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.51 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1772639 | 0.89 | F10 (0.54) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL6235191 | 0.86 | MAOB (0.47) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL1268719 | 0.86 | MAOB (0.81) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL3719734 | 0.84 | MEN1 (0.59) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL9339589 | 0.84 | MAOB (0.66) | MAOBMAOANR4A2ALDH1A1PKM | |
| SCHEMBL15761340 | 0.82 | BCHE (0.70) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL5543166 | 0.81 | NPC1 (0.51) | MAOBMAOAGAARAB9A | |
| SCHEMBL20994140 | 0.81 | MEN1 (0.56) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL20994142 | 0.81 | MEN1 (0.56) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL5546051 | 0.81 | BCHE (0.64) | MAOBBCHECYP4F2CYP4A11MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017093157-A1 | PIPERIDINE, PYRROLIDINE AND 2-OXO-1,3-OXAZINANE DERIVATIVES AS INHIBITORS OF BACTERIAL EFFLUX-PUMPS FOR THE TREATMENT OF MICROBIAL INFECTIONS | BASILEA PHARMACEUTICA AG (CH) | 2017-06-08 | — | — | WO | claimed |
| CN-105175433-A | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC | 2015-12-23 | — | — | CN | claimed |
| CN-103228643-B | As the benzoxazole derivative of histamine h 4 receptor part | BIOPROJET (FR) | 2015-11-25 | — | — | CN | claimed |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2015-10-15 | — | — | US | claimed |
| CN-103664973-A | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC | 2014-03-26 | — | — | CN | claimed |
| EP-2426106-B1 | Piperidine and Piperazine derivatives for the treatment of tumours | MERCK PATENT GMBH (DE) | 2013-07-31 | — | — | EP | claimed |
| CN-103228643-A | Benzazole derivatives as histamine H4 receptor ligands | BIOPROJET SOC CIV | 2013-07-31 | — | — | CN | claimed |
| US-8466295-B2 | Thiophene derivatives as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-06-18 | — | — | US | claimed |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-11-22 | — | — | US | claimed |
| US-20120270853-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-10-25 | — | — | US | claimed |
| EP-0607334-B1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS | DU PONT MERCK PHARMA (US) | 1997-07-30 | — | — | EP | claimed |
| US-5616578-A | Method of treating human immunodeficiency virus infection using a cyclic protease inhibitor in combination with a reverse transcriptase inhibitor | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-04-01 | — | — | US | claimed |
| US-5610294-A | VIRAL TREATMENT | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-03-11 | — | — | US | claimed |
| US-5559110-A | HIV ANTIVIRAL, GOOD SYSTEMIC ABSORPTION ADMINISTERED BY MOUTH | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-09-24 | — | — | US | claimed |
| US-5559140-A | VIRICIDES | MERRELL PHARMACEUTICALS INC. (US) | 1996-09-24 | — | — | US | claimed |
| EP-0565631-B1 | ANTI-VIRAL COMPOUNDS | MERRELL PHARMA INC (US) | 1996-09-18 | — | — | EP | claimed |
| WO-1994019008-A1 | COMBINATIONS OF RETROVIRAL INHIBITORS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-09-01 | — | — | WO | claimed |
| EP-0607334-A1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS. | DU PONT MERCK PHARMA (US) | 1994-07-27 | — | — | EP | claimed |
| WO-1993007128-A1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-04-15 | — | — | WO | claimed |
| EP-0079168-A1 | Process for making 1-(3-benzyloxyphenyl)-1,1-dimethylheptane and intermediates therefor | PFIZER INC. (US) | 1983-05-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270853-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | MAOB 589/4885BCHE 1557/4885CYP4F2 1768/4885 |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | MAOB 1736/4885BCHE 4634/4885CYP4F2 1942/4885 |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV3, TRPC3, TRPV1 | MAOB 1746/4885BCHE 4635/4885CYP4F2 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.